Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database

1

Ciltacabtagene autoleucel is associated with immune effector cell-associated enterocolitis (IEC-EC), a serious toxicity not fully characterized in trials.
2

The FDA issued a warning regarding the risk of IEC-EC in patients treated with ciltacabtagene autoleucel based on national reporting data.
3

Only ciltacabtagene autoleucel showed significant reports of IEC-EC, with 31 cases identified, indicating a potential link to this specific CAR T-cell therapy.
4

The immunological mechanisms of IEC-EC involve CAR T-cell infiltration into the gut mucosa, leading to mucosal injury and inflammation.
5

Current management of IEC-EC primarily involves systemic corticosteroids, though response rates to treatment vary.

Blood Cancer Journal (Nature Portfolio)

1